Literature DB >> 1984099

Intracavernous injection of prostaglandin E1 in combination with papaverine: enhanced effectiveness in comparison with papaverine plus phentolamine and prostaglandin E1 alone.

A Floth1, P Schramek.   

Abstract

We compared the erectile response to intracavernous injection of a combination of papaverine and prostaglandin E1 with that of a combination of papaverine and phentolamine (49 patients), and prostaglandin E1 alone (38). The degree of erection achieved was significantly better with papaverine plus prostaglandin E1 than with papaverine plus phentolamine and the duration of erection was less, although the incidence of prolonged erections (greater than 5 hours) was similar with both combinations. Papaverine with prostaglandin E1 likewise resulted in a significantly better degree of erection than prostaglandin E1 alone (prolonged erections occurred only after the drug combination). All erections subsided spontaneously and none required medical intervention throughout the study. Pain was noted only after injection of prostaglandin E1. The incidence was clearly lower (7 of 38 versus 13 of 38) after the injection of only 5 micrograms. prostaglandin E1 in combination with papaverine (although the difference is not statistically significant). Subjectively, the side effects caused by the drug combination were described as much less dramatic by the patients than after prostaglandin E1 alone. The combination of papaverine and prostaglandin E1 shows a clearly synergistic effect and might suitably replace papaverine plus phentolamine or prostaglandin E1 alone in patients who do not respond well or suffer side effects after high single doses.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1984099     DOI: 10.1016/s0022-5347(17)38246-0

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

1.  Papaverine plus prostaglandin E1 versus prostaglandin E1 alone for intracorporeal injection therapy.

Authors:  T F Zaher
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

Review 2.  Intracavernous prostaglandin E1 in erectile dysfunction.

Authors:  O I Linet; L L Neff
Journal:  Clin Investig       Date:  1994-01

Review 3.  Intracavernous alprostadil. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in erectile dysfunction.

Authors:  A P Lea; H M Bryson; J A Balfour
Journal:  Drugs Aging       Date:  1996-01       Impact factor: 3.923

4.  Clinical reliability of multi-drug intracavernous vasoactive pharmacotherapy for diabetic impotence.

Authors:  F Montorsi; G Guazzoni; F Bergamaschi; M Zucconi; P Rigatti; G Pizzini; A Miani; G Pozza
Journal:  Acta Diabetol       Date:  1994-04       Impact factor: 4.280

Review 5.  The Challenge of Erectile Dysfunction Management in the Young Man.

Authors:  Seth D Cohen
Journal:  Curr Urol Rep       Date:  2015-12       Impact factor: 3.092

Review 6.  Prostatic irradiation-induced sexual dysfunction: A review and multidisciplinary guide to management in the radical radiotherapy era (Part II on Urological Management).

Authors:  Marc J Rogers; Marigdalia K Ramirez-Fort; James A Kashanian; Seth A Broster; Jaime Matta; Sean S Mahase; Digna V Fort; M Junaid Niaz; Shearwood McClelland; Neil H Bander; Migdalia Fort; Christopher S Lange; Peter Schlegel; John P Mulhall
Journal:  Rep Pract Oncol Radiother       Date:  2020-05-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.